New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
IceCure Medical Ltd
ICCM
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

28M

Medical - Devices

Next Earning date - 20 Nov 2024

28M

Medical - Devices

Next Earning date - 20 Nov 2024

0.56USD
Shape-0.01 ( -1.04%)
favorite-chart

Relative Strenght

22
favorite-chart

Volume Buzz

-72%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

64%
OverviewChart

Quote Panel

Shape
Updated October 12, 2024
1W -5.37 % 1M -9.02 % 3M -24.77 % 1Y -34.41 %

Key Metrics

Shape

  • Market Cap

    27.93M

  • Shares Outstanding

    49.52M

  • Share in Float

    24.12M

  • Dividende

    0

  • Earning Date

    20 Nov 2024

  • Price Target

    0.5641

  • Average Volume

    588906

  • Beta

    2.656

  • Range

    0.48-1.57

  • Industry

    Medical - Devices

  • Website

    https://www.icecure-medical.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

8.26x

P/S Ratio

2.63x

P/B Ratio

0.0

Debt/Equity

-407.2%

Net Margin

$-0.3

EPS

How ICCM compares to sector?

P/E Ratio

ICCM

-2x

BRSYF 521x
OSA -1x
SRDX -392x
SSKN -1x
TNON -1x

Relative Strength

Shape

ICCM

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$8M

Shape699%

2025-Revenue

$0.92

Shape-1385%

2025-EPS

$8M

Shape-157%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.11
vs -0.03

Q4.22

arrow
arrow

N/A

-0.11
vs -0.10

Q1.23

arrow
arrow

N/A

-0.08
vs -0.12

Q2.23

arrow
arrow

N/A

-0.09
vs -0.12

Q3.23

arrow
arrow

N/A

-0.09
vs -0.11

Q4.23

arrow
arrow

N/A

-0.07
vs -0.11

Q1.24

arrow
arrow

N/A

-0.08
vs -0.08

Q2.24

arrow
arrow

N/A

-0.06
vs -0.09

Q3.24

arrow
arrow

N/A

-0.07
vs -0.09

Q4.24

arrow
arrow

N/A

-0.07
vs -0.07

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-7%

634K  vs 681K

Q4.22

arrow
arrow

-32%

939K  vs 1.4M

Q1.23

arrow
arrow

-5%

710K  vs 747K

Q2.23

arrow
arrow

+22%

937K  vs 765K

Q3.23

arrow
arrow

-48%

327K  vs 634K

Q4.23

arrow
arrow

+41%

1.3M  vs 939K

Q1.24

arrow
arrow

+4%

736.4K  vs 710K

Q2.24

arrow
arrow

+6%

996.8K  vs 937K

Q3.24

arrow
arrow

+117%

708.5K  vs 327K

Q4.24

arrow
arrow

-2%

1.3M  vs 1.3M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-26%

-0.26
vs -0.25

Q4.22

arrow
arrow

-16%

-0.16
vs -0.26

Q1.23

arrow
arrow

-16%

-0.16
vs -0.16

Q2.23

arrow
arrow

-21%

-0.21
vs -0.16

Q3.23

arrow
arrow

-27%

-0.27
vs -0.21

Q4.23

arrow
arrow

-26%

-0.26
vs -0.27

Q1.24

arrow
arrow

-31%

-0.31
vs -0.26

Q2.24

arrow
arrow

-29%

-0.29
vs -0.31

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

7

7
vs 8

-12%

Q4.22

arrow
arrow

9

9
vs 7

29%

Q1.23

arrow
arrow

7

7
vs 9

-22%

Q2.23

arrow
arrow

10

10
vs 7

43%

Q3.23

arrow
arrow

10

10
vs 10

NA

Q4.23

arrow
arrow

16

16
vs 10

60%

Q1.24

arrow
arrow

12

12
vs 16

-25%

Q2.24

arrow
arrow

14

14
vs 12

17%

Earnings Growth

Latest News

ICCM

zacks.com

5 hours ago

Bet on 5 Top-Ranked Stocks With Rising P/E
ICCM

prnewswire.com

8 hours ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
ICCM

prnewswire.com

8 hours ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
ICCM

prnewswire.com

8 hours ago

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
ICCM

prnewswire.com

8 hours ago

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
ICCM

prnewswire.com

8 hours ago

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

New Feature Coming Soon, Stay Tuned!

ShapeShape